晚期CKD患者停用与继续使用二甲双胍的全国性目标试验模拟研究
该研究基于苏格兰全国队列,纳入2010年1月至2019年4月期间使用二甲双胍并新发4期CKD(eGFR<30mL/min/1.73m2)的2型糖尿病成人,采用目标试验模拟比较停药与继续用药的结局。共识别4,278例患者,6个月内1,713例(40.1%)停用二甲双胍;停药与3年生存率较低相关(63.7% vs 70.5%;HR 1.26,95%CI 1.10-1.44),MACE发生率两组相近(HR 1.05,95%CI 0.88-1.26)。
要点
- 4期CKD后停用二甲双胍与全因死亡风险升高相关(HR 1.26,95%CI 1.10-1.44)。
- 停药组与继续组MACE发生率相近(HR 1.05,95%CI 0.88-1.26)。
- eGFR降至30以下时继续使用二甲双胍可能合适,仍需RCT证实。
核心结论
- 在4期CKD的2型糖尿病患者中,停用二甲双胍与继续使用相比3年生存率更低,而MACE风险相近。
- 作者认为eGFR降至30mL/min/1.73m2以下时继续使用二甲双胍可能是合适的,但需随机对照试验确认。
研究设计与样本
- 全国性观察性队列研究,采用目标试验模拟、克隆-删失-加权设计,并以边际结构模型做敏感性分析。
- 研究对象为苏格兰2010年1月至2019年4月间使用二甲双胍且新发4期CKD(eGFR<30mL/min/1.73m2)的2型糖尿病成人。
- 暴露为4期CKD发生后6个月内停用 versus 继续使用二甲双胍;主要结局为全因死亡,次要结局包括MACE。
主要发现
- 在371,742例2型糖尿病苏格兰居民中,识别出4,278例使用二甲双胍且新发4期CKD的患者。
- 4期CKD后6个月内1,713例(40.1%)停用二甲双胍。
- 停药组3年生存率为63.7%(95%CI 60.9-66.6),继续组为70.5%(95%CI 68.0-73.0);HR 1.26(95%CI 1.10-1.44)。
- MACE发生率两组相似:HR 1.05(95%CI 0.88-1.26)。
- 边际结构模型显示停药组全因死亡风险更高(HR 1.34,95%CI 1.08-1.67),MACE风险相似(HR 1.04,95%CI 0.81-1.33)。
临床怎么用
- 对eGFR<30mL/min/1.73m2的2型糖尿病患者,停用二甲双胍前应权衡死亡风险,不宜仅凭肾功能阈值机械停药。
- 停药决策需结合个体情况,并与患者共同讨论现有观察性证据的不确定性。
局限性
- 存在残余混杂。
- 为观察性研究,结论需随机对照试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Despite a lack of supporting evidence, current guidance recommends against the use of metformin in people with advanced kidney impairment. This observational study compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after developing stage 4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR]<30mL/min/1.73m2). STUDY DESIGN: Nationwide observational cohort study. SETTING & PARTICIPANTS: All adults with type 2 diabetes and incident stage 4 CKD in Scotland who were treated with metformin between January 2010 and April 2019. EXPOSURE: Stopping versus continuing metformin within 6 months following incident stage 4 CKD. OUTCOME: Primary outcome was all-cause mortality. Secondary outcomes included major adverse cardiovascular events (MACE). ANALYTICAL APPROACH: Target trial emulation with clone-censor-weight design and marginal structural models fit for sensitivity analyses. RESULTS: In a population of 371,742 Scottish residents with a diagnosis of type 2 diabetes before April 30, 2019, 4,278 were identified as prevalent metformin users with incident CKD stage 4. Within 6 months of developing CKD stage IV, 1,713 (40.1%) individuals discontinued metformin. Compared with continuing metformin, stopping metformin was associated with a lower 3-year survival (63.7% [95% CI, 60.9-66.6] vs 70.5% [95% CI, 68.0-73.0]; HR, 1.26 [95% CI, 1.10-1.44]), and the incidence of MACE was similar between both strategies (HR, 1.05 [95% CI, 0.88-1.26]). Marginal structural models confirmed the higher risk of all-cause mortality and similar risk of MACE in patients who stopped versus continued metformin (all-cause mortality: HR, 1.34 [95% CI, 1.08-1.67]; MACE: HR, 1.04 [95% CI, 0.81-1.33]). LIMITATIONS: Residual confounding. CONCLUSIONS: The continued use of metformin may be appropriate when eGFR falls below 30mL/min/1.73m2. Randomized controlled trials are needed to confirm these findings. PLAIN-LANGUAGE SUMMARY: Current guidance recommends against the use of metformin in people with advanced kidney impairment despite a lack of evidence. It is therefore currently unclear how the decision to stop versus continue metformin in patients who reach stage 4 CKD impacts their risk of mortality and cardiovascular events. This study showed that stopping metformin after reaching stage 4 CKD was associated with reduced survival that did not appear to be mediated by an increase in adverse cardiovascular outcomes. These findings may support the continued use of metformin in patients with advanced kidney impairment, but further research is needed to confirm these observations.
引用
- Lambourg EJ, Fu EL, McGurnaghan S, et al. Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study. Am J Kidney Dis. 2024. PMID: 39521399. doi:10.1053/j.ajkd.2024.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。